<DOC>
	<DOCNO>NCT01965223</DOCNO>
	<brief_summary>The main purpose study determine safety ( defined number participant experience ≥ 5 % toxicity 12 month post treatment ) stereotactic ablative fractionate radiotherapy versus radiosurgery oligometastatic neoplasia lung .</brief_summary>
	<brief_title>A Randomized Phase II Study Stereotactic Ablative Body Radiotherapy Metastases Lung ( TROG 13.01 SAFRON II )</brief_title>
	<detailed_description>Stereotactic Ablative Body Radiotherapy ( SABR ) excite novel radiotherapy technique deliver session . In case limited pulmonary 'oligometastases ' , SABR result long-term survival . It non-invasive associated high rate tumour control relatively low toxicity . Additionally , large dos precision radiotherapy involve may evoke strong immune response recognise attack remain tumour cell . In future , SABR may attractive alternative invasive surgery . There two SABR technique emerge Australia ; fractionate single fraction treatment . We aim conduct first clinical trial SABR patient limit pulmonary metastasis test fractionated versus single fraction treatment . The primary aim study evaluate toxicity , Quality Life , clinical efficacy cost effectiveness single fraction SABR compare multi-fraction SABR patient oligometastases lung . The secondary aim study ass immune response evoke fractionated single fraction SABR prognostic implication patient outcome .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>1 . A maximum three metastasis lung nonhaematological malignancy 2 . Tumour diameter ≤5cm 3 . Targets locate away central structure ( define 2cm beyond bifurcation lobar bronchi central airway ) . Targets proximity chest wall mediastinum meet inclusion criterion eligible . 4 . Patients must medically inoperable , technically high risk decline surgery . 1 . Previous highdose thoracic radiotherapy . 2 . Cytotoxic chemotherapy within 3 week commencement treatment , concurrently treatment . Hormonal manipulation agent exclude ( e.g . aromatase inhibitor , selective oestrogen receptor modulators , gonadotrophin release hormone receptor modulators ) 3 . Targeted agent ( sunitinib tarceva ) within 7 day commencement treatment , concurrently treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Oligometastatic</keyword>
	<keyword>Neoplasia</keyword>
	<keyword>Radiosurgery</keyword>
	<keyword>Stereotactic Ablative Body Radiotherapy</keyword>
	<keyword>SABR</keyword>
	<keyword>Metastases Lung</keyword>
	<keyword>Non Haematological</keyword>
</DOC>